Absolute Risk of Oropharyngeal Cancer After an HPV16-E6 Serology Test and Potential Implications for Screening: Results From the Human Papillomavirus Cancer Cohort Consortium
Hilary A Robbins,Aida Ferreiro-Iglesias,Tim Waterboer,Nicole Brenner,Mari Nygard,Noemi Bender,Lea Schroeder,Allan Hildesheim,Michael Pawlita,Gypsyamber D'Souza,Kala Visvanathan,Hilde Langseth,Nicolas F Schlecht,Lesley F Tinker,Ilir Agalliu,Sylvia Wassertheil-Smoller,Eivind Ness-Jensen,Kristian Hveem,Sara Grioni,Rudolf Kaaks,Maria-Jose Sánchez,Elisabete Weiderpass,Graham G Giles,Roger L Milne,Qiuyin Cai,William J Blot,Wei Zheng,Stephanie J Weinstein,Demetrius Albanes,Wen-Yi Huang,Neal D Freedman,Aimée R Kreimer,Mattias Johansson,Paul Brennan
DOI: https://doi.org/10.1200/JCO.21.01785
2022-11-01
Abstract:Purpose: Seropositivity for the HPV16-E6 oncoprotein is a promising marker for early detection of oropharyngeal cancer (OPC), but the absolute risk of OPC after a positive or negative test is unknown. Methods: We constructed an OPC risk prediction model that integrates (1) relative odds of OPC for HPV16-E6 serostatus and cigarette smoking from the human papillomavirus (HPV) Cancer Cohort Consortium (HPVC3), (2) US population risk factor data from the National Health Interview Survey, and (3) US sex-specific population rates of OPC and mortality. Results: The nine HPVC3 cohorts included 365 participants with OPC with up to 10 years between blood draw and diagnosis and 5,794 controls. The estimated 10-year OPC risk for HPV16-E6 seropositive males at age 50 years was 17.4% (95% CI, 12.4 to 28.6) and at age 60 years was 27.1% (95% CI, 19.2 to 45.4). Corresponding 5-year risk estimates were 7.3% and 14.4%, respectively. For HPV16-E6 seropositive females, 10-year risk estimates were 3.6% (95% CI, 2.5 to 5.9) at age 50 years and 5.5% (95% CI, 3.8 to 9.2) at age 60 years and 5-year risk estimates were 1.5% and 2.7%, respectively. Over 30 years, after a seropositive result at age 50 years, an estimated 49.9% of males and 13.3% of females would develop OPC. By contrast, 10-year risks among HPV16-E6 seronegative people were very low, ranging from 0.01% to 0.25% depending on age, sex, and smoking status. Conclusion: We estimate that a substantial proportion of HPV16-E6 seropositive individuals will develop OPC, with 10-year risks of 17%-27% for males and 4%-6% for females age 50-60 years in the United States. This high level of risk may warrant periodic, minimally invasive surveillance after a positive HPV16-E6 serology test, particularly for males in high-incidence regions. However, an appropriate clinical protocol for surveillance remains to be established.